Cardlytics Inc

For the period ended Jun 30, 2024. Filed Aug 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 7, 2024

CDLX$1.63-10.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations (Unaudited)

(Amounts in thousands, except per share amounts)

	Three Months EndedJune 30,		Six Months EndedJune 30,
	2024	2023	2024	2023
Revenue	$69,636	$76,701	$137,244	$141,032
Costs and expenses:
Partner Share and other third-party costs	33,258	39,170	63,801	72,554
Delivery costs	7,661	7,015	13,834	13,439
Sales and marketing expense	14,025	15,205	28,143	29,153
Research and development expense	13,470	14,847	26,518	26,411
General and administration expense	16,151	16,276	30,636	29,346
Acquisition, integration and divestiture benefit	162	(9,947)	162	(8,224)
Change in contingent consideration	(5,808)	11,258	9	(23,326)
Depreciation and amortization expense	6,529	7,200	12,779	13,775
Total costs and expenses	85,448	101,024	175,882	153,128
Operating Loss	(15,812)	(24,323)	(38,638)	(12,096)
Other (expense) income:
Interest expense, net	(1,561)	(574)	(2,380)	(582)
Foreign currency gain (loss)	99	1,389	(531)	2,778
Gain on debt extinguishment	13,017	—	13,017	—
Total other income	11,555	815	10,106	2,196
Loss before income taxes	(4,257)	(23,508)	(28,532)	(9,900)
Net Loss	$(4,257)	$(23,508)	$(28,532)	$(9,900)
Net Loss per share, basic and diluted	$(0.09)	$(0.67)	$(0.62)	$(0.29)
Weighted-average common shares outstanding, basic and diluted	49,056	34,880	46,168	34,241

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.